About Carlo Traverso
Form D filings for Bilayer Therapeutics in 2023 list Carlo Traverso as director.
Carlo Traverso first appears on SEC filings in 2023.
Experience
This experience comes from SEC filings. The years are when the filings name Carlo Traverso in the role, so the role may have started earlier or lasted longer.
Key Colleagues at Startups
The people Carlo Traverso works with at each company, as listed on that company's latest Form D.
Bilayer Therapeutics, Inc. · Form D, Aug 4, 2023
JK
Joshua Korzenik
Director
TC
Thomas Collet
President and director
RL
Robert Langer
Director
HC
Huang Yen-Chen
Director
DZ
David Zhu
Director